Nymox Pharmaceutical (NYMXF) AI Stock Analysis

• Market Cap: $18.91K
• Dividend Yield: N/A
• Average Volume (3M): 12.13K
• Price to Earnings (P/E): ―
• Beta (1Y): -2.45
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 94,540,140
• 10 Day Avg. Volume: 13,340
• 30 Day Avg. Volume: 12,129
• PEG Ratio: 0.04
• Price to Book (P/B): -1.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.60
• Enterprise Value/Market Cap: <0.01
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: ― N/A
• Price Target: ―
• Action: N/A
• Date: ―

Positive Factors

Focus on Unmet Medical Needs

Targeting unmet medical needs can lead to significant market opportunities if the company successfully develops effective treatments, particularly in aging-related conditions where demand is growing.

Negative Factors

Persistent Financial Losses

Ongoing financial losses and negative equity indicate severe financial instability, which could hinder long-term operations and the ability to fund R&D activities necessary for future growth.

Nymox Pharmaceutical Business Overview & Revenue Model

Company Description

Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship dru...

Read more

Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship dru...

How the Company Makes Money

Nymox Pharmaceutical Corporation makes money primarily through the development and commercialization of its pharmaceutical products. The company generates revenue by advancing its drug candidates through clinical trials in the hope of achieving re...

Read more

Nymox Pharmaceutical Corporation makes money primarily through the development and commercialization of its pharmaceutical products. The company generates revenue by advancing its drug candidates through clinical trials in the hope of achieving re...

Nymox Pharmaceutical Financial Statement Overview

Breakdown	Dec 2024	Dec 2023	Mar 2023	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	―
Gross Profit	-1.00K	-11.00K	-12.00K	-12.00K	―
EBITDA	-4.26M	-8.77M	-6.52M	-12.49M	-11.71M
Net Income	-4.49M	-8.84M	-6.58M	-12.54M	-11.74M
Balance Sheet
Total Assets	654.00K	627.00K	1.63M	2.03M	4.93M
Cash, Cash Equivalents and Short-Term Investments	74.00K	70.00K	1.40M	830.00K	3.61M
Total Debt	0.00	750.00K	173.00K	391.00K	426.00K
Total Liabilities	7.43M	3.80M	2.11M	1.95M	2.20M
Stockholders Equity	-6.78M	-3.17M	-482.00K	83.00K	2.73M
Cash Flow
Free Cash Flow	-2.60M	-4.06M	-5.21M	-9.83M	-10.05M
Operating Cash Flow	-2.60M	-4.06M	-5.21M	-9.82M	-10.04M
Investing Cash Flow	0.00	-3.00K	0.00	-6.00K	-13.00K
Financing Cash Flow	2.60M	2.73M	5.78M	7.04M	8.42M

Nymox Pharmaceutical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NYMXF, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.09, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 28.55 is Positive, neither overbought nor oversold. The STOCH value of 94.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NYMXF.

Nymox Pharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NYMXF	―	$18.91K	>-0.01	90.31%	―	―	―
ACXP	46 Neutral	$7.71M	-0.39	-124.74%	―	―	71.66%
MBIO	43 Neutral	$4.00M	-1.16	-34.23%	―	―	85.52%
EVGN	42 Neutral	$7.93M	-0.54	766.01%	―	-80.59%	59.44%
BOLT	42 Neutral	$7.09M	-0.23	-126.23%	0.06%	12.79%	37.93%
LYRA	37 Underperform	$354.98K	-0.01	1211.14%	―	-74.05%	73.08%